David C Hostler1, Elizabeth S Marx2, Lisa K Moores3, Sarah K Petteys1, Jordanna Mae Hostler4, Joshua D Mitchell5, Paul R Holley6, Jacob F Collen7, Brian E Foster5, Aaron B Holley8. 1. Department of Pulmonary and Critical Care Medicine, Walter Reed National Military Medical Center, Bethesda, MD. 2. Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD. 3. Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD. 4. Department of Pulmonary, Critical Care, and Sleep Medicine, Walter Reed National Military Medical Center, Bethesda, MD. 5. Department of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD. 6. Department of Informatics, US Army Medical Research Institute of Infectious Diseases, Frederick, MD. 7. Department of Pulmonary and Critical Care Medicine, San Antonio Military Medical Center, San Antonio, TX. 8. Department of Pulmonary, Critical Care, and Sleep Medicine, Walter Reed National Military Medical Center, Bethesda, MD. Electronic address: aholley9@gmail.com.
Abstract
BACKGROUND: Recent guidelines recommend assessing medical inpatients for bleeding risk prior to providing chemical prophylaxis for VTE. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding risk score (BRS) was derived from a well-defined population of medical inpatients but it has not been validated externally. We sought to externally validate the IMPROVE BRS. METHODS: We prospectively collected characteristics on admission and VTE prophylaxis data each hospital day for all patients admitted for a medical illness to the Walter Reed Army Medical Center over an 18-month period. We calculated the IMPROVE BRS for each patient using admission data and reviewed medical records to identify bleeding events. RESULTS: From September 2009 through March 2011, 1,668 inpatients met the IMPROVE inclusion criteria. Bleeding events occurred during 45 separate admissions (2.7%); 31 events (1.9%) were major and 14 (0.8%) were nonmajor but clinically relevant. Two hundred fifty-six patients (20.7%) had an IMPROVE BRS ≥ 7.0. Kaplan-Meier curves showed a higher cumulative incidence of major (P = .02) and clinically important (major plus clinically relevant nonmajor) (P = .06) bleeding within 14 days in patients with an IMPROVE BRS ≥ 7.0. An IMPROVE BRS ≥ 7.0 was associated with major bleeding in Cox-regression analysis adjusted for administration of chemical prophylaxis (OR, 2.6; 95% CI, 1.1-5.9; P = .03); there was a trend toward a significant association with clinically important bleeding (OR, 1.9; 95% CI, 0.9-3.7; P = .07). CONCLUSIONS: The IMPROVE BRS calculated at admission predicts major bleeding in medical inpatients. This model may help assess the relative risks of bleeding and VTE before chemoprophylaxis is administered. Published by Elsevier Inc.
BACKGROUND: Recent guidelines recommend assessing medical inpatients for bleeding risk prior to providing chemical prophylaxis for VTE. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding risk score (BRS) was derived from a well-defined population of medical inpatients but it has not been validated externally. We sought to externally validate the IMPROVE BRS. METHODS: We prospectively collected characteristics on admission and VTE prophylaxis data each hospital day for all patients admitted for a medical illness to the Walter Reed Army Medical Center over an 18-month period. We calculated the IMPROVE BRS for each patient using admission data and reviewed medical records to identify bleeding events. RESULTS: From September 2009 through March 2011, 1,668 inpatients met the IMPROVE inclusion criteria. Bleeding events occurred during 45 separate admissions (2.7%); 31 events (1.9%) were major and 14 (0.8%) were nonmajor but clinically relevant. Two hundred fifty-six patients (20.7%) had an IMPROVE BRS ≥ 7.0. Kaplan-Meier curves showed a higher cumulative incidence of major (P = .02) and clinically important (major plus clinically relevant nonmajor) (P = .06) bleeding within 14 days in patients with an IMPROVE BRS ≥ 7.0. An IMPROVE BRS ≥ 7.0 was associated with major bleeding in Cox-regression analysis adjusted for administration of chemical prophylaxis (OR, 2.6; 95% CI, 1.1-5.9; P = .03); there was a trend toward a significant association with clinically important bleeding (OR, 1.9; 95% CI, 0.9-3.7; P = .07). CONCLUSIONS: The IMPROVE BRS calculated at admission predicts major bleeding in medical inpatients. This model may help assess the relative risks of bleeding and VTE before chemoprophylaxis is administered. Published by Elsevier Inc.
Entities:
Keywords:
antibiotic therapy; deep venous thrombosis; pulmonary embolism
Authors: Andrea J Darzi; Allen B Repp; Frederick A Spencer; Rami Z Morsi; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Kenneth A Bauer; Allison E Burnett; Mary Cushman; Francesco Dentali; Susan R Kahn; Suely M Rezende; Neil A Zakai; Arnav Agarwal; Samer G Karam; Tamara Lotfi; Wojtek Wiercioch; Reem Waziry; Alfonso Iorio; Elie A Akl; Holger J Schünemann Journal: Blood Adv Date: 2020-10-13
Authors: Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet Journal: Nat Rev Gastroenterol Hepatol Date: 2021-08-27 Impact factor: 46.802
Authors: Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch Journal: Blood Adv Date: 2018-11-27
Authors: Ruben J Eck; Wouter Bult; Jørn Wetterslev; Reinold O B Gans; Karina Meijer; Iwan C C van der Horst; Frederik Keus Journal: J Clin Med Date: 2019-11-21 Impact factor: 4.241
Authors: Ignacio Novo-Veleiro; Lucía Alvela-Suárez; Alba Costa-Grille; Javier Suárez-Dono; Fernando Ferrón-Vidan; Antonio Pose-Reino Journal: BMJ Open Date: 2018-05-14 Impact factor: 2.692